Innate Pharma Return On Equity vs. Shares Owned By Insiders
| IPH Stock | EUR 1.37 0.05 3.52% |
For Innate Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Innate Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Innate Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Innate Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Innate Pharma over time as well as its relative position and ranking within its peers.
Innate |
Innate Pharma Shares Owned By Insiders vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Innate Pharma's current stock value. Our valuation model uses many indicators to compare Innate Pharma value to that of its competitors to determine the firm's financial worth. Innate Pharma is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in shares owned by insiders category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Innate Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Innate Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Innate Shares Owned By Insiders vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Innate Pharma |
| = | -0.17 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Innate Pharma |
| = | 22.50 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Innate Shares Owned By Insiders Comparison
Innate Pharma is currently under evaluation in shares owned by insiders category among its peers.
Innate Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Innate Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Innate Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Innate Pharma's change in net profit over the period of time. It can combine multiple indicators of Innate Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company was founded in 1999 and is based in Marseille, France. INNATE PHARMA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 191 people.
Innate Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Innate Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Innate Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Innate Pharma's important profitability drivers and their relationship over time.
Use Innate Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Innate Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will appreciate offsetting losses from the drop in the long position's value.Innate Pharma Pair Trading
Innate Pharma Pair Trading Analysis
The ability to find closely correlated positions to Innate Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Innate Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Innate Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Innate Pharma to buy it.
The correlation of Innate Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Innate Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Innate Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Innate Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Innate Pharma position
In addition to having Innate Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banks - Regional Thematic Idea Now
Banks - Regional
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banks - Regional theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks - Regional Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
To fully project Innate Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Innate Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Innate Pharma's income statement, its balance sheet, and the statement of cash flows.